Loading

This agenda is still in development. All sessions and timings are subject to regular change at this time. 

  1. Sunrise Fun Run along the bayside in partnership with Avery's Hope
    Hilton Bayfront Hotel
    19-Jan-2027
    • Networking
    Join Phacilitate and Averys Hope for the annual fun run along the bayside whilst raising money to support ultra rare and undiagnosed pediatric GI patient families. All proceeds will be going straight to the patient.
  2. WIAT Breakfast
    Theatre 1
    21-Jan-2027
    • Women in Advanced Therapies
    Interactive discussions over breakfast
  3. Dedicated exhibition hour
    Exhibition Hall
    21-Jan-2027
    • Networking
  4. Dedicated exhibition hour
    Exhibition Hall
    20-Jan-2027
    • Networking
  5. Workshop: ThermoFisher
    Theatre 2
    19-Jan-2027
    • Workshop
    ThermoFisher
  6. Dedicated exhibition hour
    Exhibition Hall
    19-Jan-2027
    • Networking
  7. Plenary: How must healthcare and industry models evolve to achieve the elusive goal of improved patient access?
    Theatre 1
    19-Jan-2027
    • Plenary
    Anthony Davies, Founder & CEO - Dark Horse Consulting Group
  8. Plenary: Plotting a course to sustainable future success for the cell & gene therapy industry
    Theatre 1
    20-Jan-2027
    • Plenary
    Sven Kili, Partner - Saisei Ventures
  9. Session 6: Do we need to rethink our approach to overcoming resistance in the TME?
    Theatre 1
    21-Jan-2027
    • Streamlining Early Development to Enable Rapid Clinical Proof of Concept
  10. Phacilitate TV part 1
    Phacilitate Stage
    19-Jan-2027
    • Phacilitate Stage
    Benjamin McLeod, Founder - Convey Bio
    Jeffrey Martin, Founder and investor strategy partner for early-stage biotech - Flyte Bio
  11. Investment Summit
    Indigo B
    18-Jan-2027
    • Investment Summit
  12. Session 7: What does the future hold for allogeneic cell therapy?
    Theatre 4
    21-Jan-2027
    • Commercializing Advanced Therapies
  13. Phacilitate TV Part 3
    Phacilitate Stage
    20-Jan-2027
    • Phacilitate Stage
    Benjamin McLeod, Founder - Convey Bio
    Jeffrey Martin, Founder and investor strategy partner for early-stage biotech - Flyte Bio
  14. Session 8: How and where is innovation in both systemic and local delivery enabling the migration of advanced therapies into emerging indications and therapeutic areas?
    Theatre 3
    21-Jan-2027
    • Innovation in Gene Delivery
  15. Session 5: The Solution Sprint
    Theatre 5
    21-Jan-2027
    • Empowering Patients, Delivering Access (in Partnership with the Emily Whitehead Foundation)
     Every initiative represented in the track commits a 30/60/90-day pledge on stage: CAR-T Vision 2030, The Access Coalition at ARM, COA’s Cell Therapy Task Force, The Foundation and its stakeholders, a ...
  16. Session 8: Accelerated approval pathways: Do the benefits really outweigh the costs?
    Theatre 4
    21-Jan-2027
    • Commercializing Advanced Therapies
    Noelle Harff, Technology and Biotech Reporter - San Diego Union-Tribune
  17. Session 8: How is the advanced therapies manufacturing and supply chain infrastructure evolving worldwide in support of global clinical development opportunities
    Theatre 2
    21-Jan-2027
    • Manufacturing, CMC and Supply Chain
  18. Session 9: Next-generation vector systems and emerging payloads – how and where can they enable the cell & gene therapy field to advance?
    Theatre 3
    21-Jan-2027
    • Innovation in Gene Delivery
  19. Morning coffee break and networking
    Exhibition Hall
    20-Jan-2027
    • Networking
  20. Morning coffee break and networking
    Exhibition Hall
    19-Jan-2027
    • Networking
  21. Workshop: Beyond Viral Vectors: An End-to-End Platform for Rapid CAR-T and CAR-NK Generation
    Theatre 1
    20-Jan-2027
    • Workshop
    Are you exploring alternatives to viral vectors for cell engineering? Looking for ways to accelerate CAR-T and CAR-NK development while simplifying manufacturing workflows and reducing process complex ...
    Sartorius
    Rok Sekirnik, Head of Process Development for mRNA and pDNA - Sartorius
    Claire Gueguen, R&D Life Sciences Manager - Sartorius
  22. Workshop: From cell selection to fill-finish: Building connected cell therapy manufacturing workflows
    Theatre 2
    20-Jan-2027
    • Workshop
    Cell and gene therapies continue to demonstrate transformative clinical potential, but manufacturing complexity remains a significant barrier to broader patient access. As more therapies progress toward commercial scale, technology providers are innovating beyond individual unit operations to develop integrated solutions that developers and CDMOs can incorporate into their manufacturing workflows. Through collaboration across the ecosystem, these technologies have the potential to improve operational efficiency, support scalability, reduce manual process steps, and help future-proof manufacturing for growing commercial demand.
    Fresenius Kabi
    Nicholas Boyd, Head of Biology, Applications & Validation - Celleo
    Amelia Heesen, Field Application Specialist, Cell & Gene Therapy Technologies - Fresenius Kabi
    Jeffrey Cram, Vice President of Process Development - Elevatebio
  23. CDMO strategy for the long term
    Theatre 6
    20-Jan-2027
    • CGT Connect
    An interactive session examining how advanced therapy developers can establish effective CDMO strategies that support their programmes as they progress through development and towards commercialisatio ...
    Carlos Candido, Vice President, Cell Therapy Operations - Eledon Pharmaceuticals
  24. Morning coffee break: Brunch is served
    Exhibition Hall
    21-Jan-2027
    • Networking
  25. Session 1: Where will cell & gene therapies sit in the cancer armamentarium of the future?
    Theatre 4
    19-Jan-2027
    • Commercializing Advanced Therapies
    Miguel Forte, CEO - Kiji Therapeutics
  26. Session 1: Which process and analytical tools have the requisite flexibility, scalability, and cost-effectiveness to enable rapid clinical translation while laying the groundwork for later development and commercialisation? Part 1
    Theatre 1
    19-Jan-2027
    • Streamlining Early Development to Enable Rapid Clinical Proof of Concept
  27. Session 4: How and where to harness NAMs in support of in vivo preclinical models in practice? Learning lessons from recent regulatory responses to IND applications
    Theatre 1
    20-Jan-2027
    • Streamlining Early Development to Enable Rapid Clinical Proof of Concept
  28. Session 4: What are the strategic and technological manufacturing and supply chain advances required to enable commercial CAR-T cell therapies to scale beyond 20% of eligible patients?
    Theatre 4
    20-Jan-2027
    • Commercializing Advanced Therapies
    Andy Lin, Vice President & Global Head of Individualized and Cell Therapy Development, Pharma Technical - Genentech
  29. Session 1: How are key gene delivery platforms stacking up both in vivo and ex vivo to address concerns around safety, immunogenicity, durability, efficacy, and redosing potential?
    Theatre 3
    19-Jan-2027
    • Innovation in Gene Delivery
  30. Session 1: Autologous and allogeneic cell therapies – what’s the latest progress in reducing process timeframes and cost of goods while enhancing scalability, quality, and consistency?
    Theatre 2
    19-Jan-2027
    • Manufacturing, CMC and Supply Chain
    Sarah Yuan, Chief Technology Officer - Cabaletta Bio
  31. Session 5: Viral Vectors - Innovation in AAV: Building the next generation of safe, scalable and affordable vector platforms
    Theatre 3
    20-Jan-2027
    • Innovation in Gene Delivery
  32. Live podcast: Confessions of a rare disease mama
    Phacilitate Stage
    19-Jan-2027
    • Phacilitate Stage
    Join us at the Phacilitate stage for this live podcast where our guests will be completely unfiltered talking about the important topics keeping you up at night. 
    Jillian Arnold, Speaker, Author, Podcast Host, Advocate, - Confessions of a Rare Disease Mama
    Caryl Harris, Co-Founder and Executive Director - Avery's Hope
  33. Live podcast with Ben and Jeff
    Phacilitate Stage
    20-Jan-2027
    • Phacilitate Stage
    Join us at the Phacilitate stage for this live podcast where our guests will be completely unfiltered talking about the important topics keeping you up at night. 
    Jeffrey Martin, Founder and investor strategy partner for early-stage biotech - Flyte Bio
    Benjamin McLeod, Founder - Convey Bio
  34. Closing plenary: Defining key takeaways and setting future goals/actions for all stakeholders in enabling improved patient access to cell & gene therapies
    21-Jan-2027
  35. Regulator drop in
    Theatre 6
    19-Jan-2027
    • CGT Connect
    An informal, interactive session providing delegates with the opportunity to discuss regulatory questions and challenges directly with experienced regulatory professionals. Through short, focused disc ...
    Deborah Hursh, Consultant - Hursh Cell Therapy Consulting
    Chris Juenger, Director, Lead, North America Regulatory Science, Policy and Intelligence - CSL
  36. How do you plan and execute successful overseas IIT in the APAC and Australian regions?
    Theatre 6
    20-Jan-2027
    • CGT Connect
    An interactive session exploring the opportunities and challenges of conducting investigator-initiated trials (IITs) across the APAC and Australasian regions. Bringing together regulatory and industry ...
    Miguel Forte, CEO - Kiji Therapeutics
    Yoshiaki Maruyama, Director, Office of Cellular and Tissue-based Products - Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  37. Break and networking
    Hilton Bayfront Hotel
    18-Jan-2027
    • Networking
  38. Phacilitate hub meet up: Navigating the complex IP landscape for delivery platforms
    Phacilitate Hub
    20-Jan-2027
    • Innovation in Gene Delivery
    Phacilitate Hub Meet Up: Come and meet like minded individuals that are all facing the same challenge as you in a laid back networking setting at the Phacilitate hub. If you would like to discuss 'nav ...
  39. Session 1: Referral & Awareness
    Theatre 5
    19-Jan-2027
    • Empowering Patients, Delivering Access (in Partnership with the Emily Whitehead Foundation)
    Why community oncologists do not refer, and what it would take to change that. The session opens with the referral economics, the chemotherapy and stem cell transplant revenue community oncologists lo ...
  40. Session 3: Site Readiness & Manufacturing Handoff
    Theatre 5
    20-Jan-2027
    • Empowering Patients, Delivering Access (in Partnership with the Emily Whitehead Foundation)
    The decentralization debate, named for what it is. The room is split along predictable lines: academic GMP facilities favour decentralization; pharma cell therapy Presidents favour centralization. The ...
  41. Innovation zone: Enabling technology & tools
    Innovation Zone
    19-Jan-2027
    • Innovation Zone
  42. Innovation zone: Clinical development & translational tools
    Exhibition Hall
    20-Jan-2027
    • Innovation Zone
  43. Session 2: Non-viral delivery Part 1 - R&D and Regulatory focus
    Theatre 3
    19-Jan-2027
    • Innovation in Gene Delivery
  44. Session 2: Innovation in viral vector manufacturing
    Theatre 2
    19-Jan-2027
    • Manufacturing, CMC and Supply Chain
    Ashish Saksule, Associate Director - Vertex Pharmaceuticals
  45. Session 5: Stepping back and reviewing the advanced therapy sector’s approach to automation
    Theatre 2
    20-Jan-2027
    • Manufacturing, CMC and Supply Chain
    Greg Russotti, Chief Technology & Manufacturing Officer - Century Therapeutics
  46. Phacilitate hub meet up: How to turn clinical success into commercial success
    Phacilitate Hub
    19-Jan-2027
    • Commercializing Advanced Therapies
    Phacilitate Hub Meet Up: Come and meet like minded individuals that are all facing the same challenge as you in a laid back networking setting at the Phacilitate hub. If you would like to discuss 'how ...
  47. Workshop: Cytiva
    Theatre 1
    19-Jan-2027
    • Workshop
    Cytiva
  48. China IIT workshop
    Indigo B
    18-Jan-2027
    • Workshop
    How to successfully set up, conduct, and leverage the data from Investigator-Initiated Trials (IITs) in China? Learning lessons from real-world experiences. Strategic insights, case studies and audien ...
    Eugene Jiaxian Wang, Founder & CEO - HELP Therapeutics
    Andrew Lee, Co-Founder & CEO - Spot Biosystems
    Jianhua Feng, Director, Department of Pediatrics - Zhejiang University School of Medicine
  49. Dedicated exhibition hour: Lunch served
    Exhibition Hall
    19-Jan-2027
    • Networking
  50. The Big Debate: In vivo CAR-T - is it the future or just more hype?
    Phacilitate Stage
    19-Jan-2027
    • Phacilitate Stage
    Michael Klichinsky, CSO - Nava Therapeutics
  51. The Big Debate: Will AAV in vivo gene therapy still dominate in 2030?
    Phacilitate Stage
    20-Jan-2027
    • Phacilitate Stage
  52. Founders Forum
    Indigo A
    18-Jan-2027
    • Founders Forum
  53. Dedicated exhibition hour: Lunch served
    Exhibition Hall
    20-Jan-2027
    • Networking
  54. Workshop: Invetech
    Theatre 1
    20-Jan-2027
    • Workshop
    Invetech
  55. Workshop: Cellular Origins
    Theatre 2
    19-Jan-2027
    • Workshop
    Cellular Origins
  56. Meet the CRO
    Theatre 6
    19-Jan-2027
    • CGT Connect
    An interactive session bringing together contract research organisations (CROs) and advanced therapy developers to discuss the practical considerations involved in planning and delivering cell and gen ...
  57. Phacilitate hub meet up: When is the right time for biotech too pursue a processing technology platform
    Phacilitate Hub
    19-Jan-2027
    • Manufacturing, CMC and Supply Chain

    Phacilitate Hub Meet Up: Come and meet like minded individuals that are all facing the same challenge as you in a laid back networking setting at the Phacilitate hub.

    If you would like to discuss 'when is the right time for biotech to pursue a processing technology platform', meet at the hub at 2.15pm

  58. Session 2: Advanced therapy products for autoimmune diseases
    Theatre 4
    19-Jan-2027
    • Commercializing Advanced Therapies
    Samik Basu, CSO - Cabaletta Bio
  59. Session 5: COGs control - how far do we still have to go, and what should be our key targets for further progress in reducing manufacturing and supply chain costs?
    Theatre 4
    20-Jan-2027
    • Commercializing Advanced Therapies
    Gregory Whitehead, Executive Vice President & Chief Technical & Quality Manager - Editas Medicine
  60. Session 2: Which process and analytical tools have the requisite flexibility, scalability, and cost-effectiveness to enable rapid clinical translation while laying the groundwork for later development and commercialization? Part 2
    Theatre 1
    19-Jan-2027
    • Streamlining Early Development to Enable Rapid Clinical Proof of Concept
  61. Innovation zone: Delivery, targeting & in vivo technologies
    Innovation Zone
    19-Jan-2027
    • Innovation Zone
  62. Innovation zone: Gene therapeutic developers
    Innovation Zone
    20-Jan-2027
    • Innovation Zone
  63. Session 3: Non-viral delivery Part 2 - Manufacturing, CMC and supply chain focus
    Theatre 3
    19-Jan-2027
    • Innovation in Gene Delivery
  64. Phacilitate TV part 2
    Phacilitate Stage
    19-Jan-2027
    • Phacilitate Stage
    Benjamin McLeod, Founder - Convey Bio
    Jeffrey Martin, Founder and investor strategy partner for early-stage biotech - Flyte Bio
  65. Session 6: Cell therapy product characterization and QC
    Theatre 2
    20-Jan-2027
    • Manufacturing, CMC and Supply Chain
    Steven Falcone, COO - Elevatebio
  66. Session 6: Viral Vectors - Innovation in LVV: building the next generation of safe, scalable, and affordable vector platforms
    Theatre 3
    20-Jan-2027
    • Innovation in Gene Delivery
    Nathalie Clément, Senior Vice President, Vector Development - Siren Biotechnology
  67. Phacilitate hub meet up: How can developers accelerate the path to clinical proof of concept without making early decisions that compromise future scalability, regulatory readiness or commercial viability
    Phacilitate Hub
    20-Jan-2027
    • Streamlining Early Development to Enable Rapid Clinical Proof of Concept
    Phacilitate Hub Meet Up: Come and meet like minded individuals that are all facing the same challenge as you in a laid back networking setting at the Phacilitate hub. If you would like to discuss 'how ...
  68. Phacilitate TV part 4
    Phacilitate Stage
    20-Jan-2027
    • Phacilitate Stage
    Benjamin McLeod, Founder - Convey Bio
    Jeffrey Martin, Founder and investor strategy partner for early-stage biotech - Flyte Bio
  69. AI Workshop
    Theatre 6
    19-Jan-2027
    • CGT Connect
    An interactive workshop exploring the current and emerging applications of artificial intelligence across the cell and gene therapy industry. The session will begin with a panel discussion examining h ...
    Irene Rombel, CEO and Co-Founder - BioCurie
    Jason Beckwith, Leader in Residence - University of Leeds
    Kyle Carter, Senior Director, Quality, Data Systems and Data Processes - Kite Pharma
  70. How to reduce the current fragility of cell & gene therapy raw materials supply chains?
    Theatre 6
    20-Jan-2027
    • CGT Connect
    An interactive discussion examining the vulnerabilities and challenges affecting raw material supply chains for cell and gene therapies. The session will explore the factors contributing to supply cha ...
    Lili Belcastro, Associate Director - Bristol Myers Squibb
    Basak Clements, Founder & Senior Scientific Advisor - biomatria
    Amit Joshi, Senior Director, Strategic Sourcing - Iovance Biotherapeutics
  71. Session 2: Eligibility & Payer Authorization
    Theatre 5
    19-Jan-2027
    • Empowering Patients, Delivering Access (in Partnership with the Emily Whitehead Foundation)
     The second-opinion problem and the prior-authorization wall. Presenting the direct-to-patient referral and navigation model that removes the financial friction at the point of eligibility assessment. ...
  72. Session 4: Infusion & Community Delivery
    Theatre 5
    20-Jan-2027
    • Empowering Patients, Delivering Access (in Partnership with the Emily Whitehead Foundation)
    What community delivery actually looks like in practice. A newly up and running community program leads the effort. The patient programs and the patient navigator role are presented as the connective ...
  73. Session 3: What does ‘phase-appropriate’ actually look like in early process and product development?
    Theatre 1
    19-Jan-2027
    • Streamlining Early Development to Enable Rapid Clinical Proof of Concept
  74. Session 3: iPSCs – what does the future hold? Part 1
    Theatre 2
    19-Jan-2027
    • Manufacturing, CMC and Supply Chain
    Kim Raineri, Chief Technology Officer - Aspen Neuroscience
  75. Session 7: Gene therapy product characterization and QC
    Theatre 2
    20-Jan-2027
    • Manufacturing, CMC and Supply Chain
  76. Roundtable Discussions
    Mezzanine Level
    20-Jan-2027
  77. Live podcast: Business of biotech
    Phacilitate Stage
    19-Jan-2027
    • Phacilitate Stage
    Join us at the Phacilitate stage for this live podcast where our guests will be completely unfiltered talking about the important topics keeping you up at night. 
    Ben Comer, Chief Editor and Host - Life Science Leader, Business of Biotech
  78. Live podcast: Operational challenges in CGT drug development
    Phacilitate Stage
    20-Jan-2027
    • Phacilitate Stage
    Join us at the Phacilitate stage for this live podcast where our guests will be completely unfiltered talking about the important topics keeping you up at night. 
    Nicholas Crudele, Producer - Out of the lab: Operationalizing cell and gene therapy
  79. Welcome drinks on the terrace
    Hilton Bayfront Terrace
    18-Jan-2027
    • Networking
    This drinks kicks off the event and always has such a good buzz. Everyone is ready to make new connections whilst enjoying the views of the bay from the terrace. 
  80. Session 5: Innovation in early clinical trial design and execution: how to streamline the pathway to rapid clinical proof of concept while avoiding the pitfalls?
    Theatre 1
    20-Jan-2027
    • Streamlining Early Development to Enable Rapid Clinical Proof of Concept
  81. The Big Debate: Modular or platform manufacturing technology – which will hold sway in cell & gene therapy over the coming decade?
    Phacilitate Stage
    20-Jan-2027
    • Phacilitate Stage
  82. Session 3: How to ensure the long-term future of advanced therapies for rare, ultra-rare and nano-rare diseases?
    Theatre 4
    19-Jan-2027
    • Commercializing Advanced Therapies
  83. Session 6: Supply chain as a commercial strategy
    Theatre 4
    20-Jan-2027
    • Commercializing Advanced Therapies
  84. Innovation zone: Cell therapeutics developers
    Innovation Zone
    19-Jan-2027
    • Innovation Zone
  85. Innovation zone: Manufacturing, scaleup & COGs reduction
    Innovation Zone
    20-Jan-2027
    • Innovation Zone
  86. Session 4: Genome and epigenome editing: troubleshooting the pathway to clinic and the marketplace beyond
    Theatre 3
    19-Jan-2027
    • Innovation in Gene Delivery
  87. Session 4: iPSCs – what does the future hold? Part 2
    Theatre 2
    19-Jan-2027
    • Manufacturing, CMC and Supply Chain
    Kim Raineri, Chief Technology Officer - Aspen Neuroscience
  88. Live podcast: Operational challenges in CGT drug development
    Phacilitate Stage
    19-Jan-2027
    • Phacilitate Stage
    Join us at the Phacilitate stage for this live podcast where our guests will be completely unfiltered talking about the important topics keeping you up at night. 
    Nicholas Crudele, Producer - Out of the lab: Operationalizing cell and gene therapy
    Basak Clements, Founder & Senior Scientific Advisor - biomatria
  89. Session 7: The more we learn the less we know. How can we leverage an increasingly high-resolution picture of viral vector quality to the benefit of gene therapy product consistency and safety?
    Theatre 3
    20-Jan-2027
    • Innovation in Gene Delivery
  90. Patient Plenary
    Indigo B
    18-Jan-2027
    • Plenary
    Four advanced therapy patients share their experiences and corresponding insights across a range of indications and modalities  
    Tom Whitehead, Co-Founder - Emily Whitehead Foundation
    Jillian Arnold, Speaker, Author, Podcast Host, Advocate, - Confessions of a Rare Disease Mama
    Caryl Harris, Co-Founder and Executive Director - Avery's Hope
  91. Dedicated exhibition hour and poster zone
    Exhibition Hall
    19-Jan-2027
    • Networking

    Drinks are served from 5pm. 

    Join us at the innovation zone to explore all the exciting innovation happening in the field. During this hour the poster presenters will be happy to take you through their inspirational new science. 

  92. Dedicated exhibition hour and poster zone
    Exhibition Hall
    20-Jan-2027
    • Networking
    Join us at the innovation zone to explore all the exciting innovation happening in the field. During this hour the poster presenters will be happy to take you through their inspirational new science. 
  93. Workshop: In Vivo CAR-T: Turning clinical promise into an IND-ready program
    Theatre 1
    19-Jan-2027
    • Workshop
    ProBio
    Jin Yin, CTO - ProBio
  94. Workshop: Sartorius
    Theatre 2
    19-Jan-2027
    • Workshop
    Sartorius
  95. WIAT Workshop
    Theatre 1
    20-Jan-2027
    • Women in Advanced Therapies
  96. Exhibition networking drinks
    Exhibition Hall
    20-Jan-2027
    • Networking
    Join us for drinks in the exhibition to find new partnerships, spark new ideas and explore the innovation taking place in the field to make cell and gene therapy commercial. 
  97. Curechella festival
    Padres Baseball Stadium
    19-Jan-2027
    • Networking
    Phacilitate and The Emily Whitehead Foundation presents Curechella, a fundraising festival to support patients gaining access to the life changing treatments you are creating. A range of bands, merch ...